表儿茶素作用机制 - Medchemexpress - MCE中国

1、Product Data Sheet(-)-EpicatechinCat. No.: HY-N0001CAS No.: 490-46-0分式: CHO分量: 290.27作靶点: COX; Ferroptosis; Endogenous Metabolite作通路: Immunology/Inflammation; Apoptosis; Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (344.51

2、mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 3.4451 mL 17.2253 mL 34.4507 mL5 mM 0.6890 mL 3.4451 mL 6.8901 mL10 mM 0.3445 mL 1.7225 mL 3.4451 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 储存时，请在 6 个内使，-20C 储存时，请在 1 个内使。

3、体内实验请根据您的实验动物和给药式选择适当的溶解案。以下溶解案都请先按照 In Vitro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (8.61 mM); Clear solution此案可获得 2.5 mg/mL (8.61

4、 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 25.0 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (8.61 mM); Clear solution此案可获得 2.5 mg/mL (8.61 mM，饱和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液为例，

5、取 100 L 25.0 mg/mL 的澄均匀。DMSO 储备液加到 900 L 20% 的 SBE-CD 理盐溶液中，混合3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (8.61 mM); Clear solution此案可获得 2.5 mg/mL (8.61 mM，饱和度未知) 的澄 溶液，此案不适于实验周 期在半个以上的实验。以 1 mL 作液为例，取 100 L 25.0 mg/mL 的澄 DMSO 储备液加到 900 L 油中，混合均匀。BIOLOGICAL ACTIVITY物活性 (-)-Epicatechin 抑

6、制环加氧酶-1 (COX-1) , IC50为 3.2 M。(-)-Epicatechin 通过阻断 NF-B 的 p65 亚基的核定位来抑制 IL-1 诱导的 iNOS 表达。IC & Target COX-1 Human Endogenous Metabolite3.2 M (IC50) (批量添加)体外研究 (-)-Epicatechin exhibits 95% inhibitory activity at 70 g/mL against cyclooxygenase-1 (COX-1) with an IC50 of 3.2 M1. (-)-Epicatechin inhibits

7、the IL-1-induced expression of iNOS by blocking the nuclear localization of the p65subunit of NF-B. In RINm5F cells, (-)-Epicatechin is shown to block the inhibition of insulin release after addition ofIL-1. Additionally, (-)-Epicatechin is shown to inhibit the proliferation of Hodgkins lymphoma cel

8、ls and Jurkat T cells,which is attributed to the ability of (-)-Epicatechin to inhibit the binding of NF-B to DNA in these cells. In humancolorectal cancer HCT-116 cells, combining 20 M Panaxadiol with 150, 200, or 250 M (-)-Epicatechin results ingrowth inhibition of 51%, 97%, and 95%, respectively.

9、 The combination also increases the apoptosis level by 11.9%,16.6%, and 25.8%, as examined by annexin V/PI staining2.体内研究 Animals receive 1 mg/kg of (-)-Epicatechin or water (vehicle) via oral gavage (twice daily). Exercise groups undergo 15days of treadmill exercise. Significant increases in treadm

10、ill performance (50%) and enhanced in situ muscle fatigueresistance (30%) are observed with (-)-Epicatechin3.PROTOCOLAnimal Mice3Administration 3 1-year-old, male C57BL/6N mice (n=25) are randomized into four groups. Mice in the (-)-Epicatechin groups 3 and 4 are given 1.0 mg/kg twice a day (morning

11、 and evening) for 15 consecutive days, whereas animals in the controlgroups 1 and 2 receive the vehicle (water). Both (-)-Epicatechin and vehicle are administered via oral gavage3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Int J Insect

12、Sci. 2018 Feb 28;10:1179543318758409. Viruses. 2020 Feb 4;12(2). pii: E176.See more customer validations on HYPERLINK www.MedChemE www.MedChemEPage 2 of 3 www.MedChemEREFERENCES1. Waffo-Tguo P, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (V

13、itis vinifera) cell cultures. NutrCancer. 2001;40(2):173-9.2. Shay J, et al. Molecular Mechanisms and Therapeutic Effects of (-)-Epicatechin and Other Polyphenols in Cancer, Inflammation, Diabetes, andNeurodegeneration. Oxid Med Cell Longev. 2015;2015:181260.3. Nogueira L, et al. (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle. J Physiol. 2011 Sep 15;589(Pt 18):4615-31.McePdfHeightCaution: